Book contents
- Frontmatter
- Dedication
- Contents
- List of contributors
- Editor's preface
- PART I INTRODUCTION AND GENERAL PRINCIPLES
- 1 Pathophysiology of nervous system diseases
- 2 Genetics of common neurological disorders
- 3 Repeat expansion and neurological disease
- 4 Cell birth and cell death in the central nervous system
- 5 Neuroprotection in cerebral ischemia
- 6 Promoting recovery of neurological function
- 7 Measurement of neurological outcomes
- 8 Principles of clinical neuro-epidemiology
- 9 Principles of therapeutics
- 10 Windows on the working brain: functional imaging
- 11 Windows on the working brain: magnetic resonance spectroscopy
- 12 Windows on the working brain: evoked potentials, magnetencephalography and depth recording
- PART II DISORDERS OF HIGHER FUNCTION
- PART III DISORDERS OF MOTOR CONTROL
- PART IV DISORDERS OF THE SPECIAL SENSES
- PART V DISORDERS OF SPINE AND SPINAL CORD
- PART VI DISORDERS OF BODY FUNCTION
- PART VII HEADACHE AND PAIN
- PART VIII NEUROMUSCULAR DISORDERS
- PART IX EPILEPSY
- PART X CEREBROVASCULAR DISORDERS
- PART XI NEOPLASTIC DISORDERS
- PART XII AUTOIMMUNE DISORDERS
- PART XIII DISORDERS OF MYELIN
- PART XIV INFECTIONS
- PART XV TRAUMA AND TOXIC DISORDERS
- PART XVI DEGENERATIVE DISORDERS
- PART XVII NEUROLOGICAL MANIFESTATIONS OF SYSTEMIC CONDITIONS
- Complete two-volume index
- Plate Section
11 - Windows on the working brain: magnetic resonance spectroscopy
from PART I - INTRODUCTION AND GENERAL PRINCIPLES
Published online by Cambridge University Press: 05 August 2016
- Frontmatter
- Dedication
- Contents
- List of contributors
- Editor's preface
- PART I INTRODUCTION AND GENERAL PRINCIPLES
- 1 Pathophysiology of nervous system diseases
- 2 Genetics of common neurological disorders
- 3 Repeat expansion and neurological disease
- 4 Cell birth and cell death in the central nervous system
- 5 Neuroprotection in cerebral ischemia
- 6 Promoting recovery of neurological function
- 7 Measurement of neurological outcomes
- 8 Principles of clinical neuro-epidemiology
- 9 Principles of therapeutics
- 10 Windows on the working brain: functional imaging
- 11 Windows on the working brain: magnetic resonance spectroscopy
- 12 Windows on the working brain: evoked potentials, magnetencephalography and depth recording
- PART II DISORDERS OF HIGHER FUNCTION
- PART III DISORDERS OF MOTOR CONTROL
- PART IV DISORDERS OF THE SPECIAL SENSES
- PART V DISORDERS OF SPINE AND SPINAL CORD
- PART VI DISORDERS OF BODY FUNCTION
- PART VII HEADACHE AND PAIN
- PART VIII NEUROMUSCULAR DISORDERS
- PART IX EPILEPSY
- PART X CEREBROVASCULAR DISORDERS
- PART XI NEOPLASTIC DISORDERS
- PART XII AUTOIMMUNE DISORDERS
- PART XIII DISORDERS OF MYELIN
- PART XIV INFECTIONS
- PART XV TRAUMA AND TOXIC DISORDERS
- PART XVI DEGENERATIVE DISORDERS
- PART XVII NEUROLOGICAL MANIFESTATIONS OF SYSTEMIC CONDITIONS
- Complete two-volume index
- Plate Section
Summary
Nuclear magnetic resonance (NMR) spectroscopy is an observational technique based on detection of signals from magnetic atomic nuclei such as 1H, 31P, 13C, 15N, and 17O. It is most familiar to physicians and the public as magnetic resonance imaging (MRI), which uses the strong signal from water protons to make the most highly detailed pictures of living tissue available from any non-invasive method. In consequence, MRI, including its special forms magnetic resonance angiography, diffusion-weighted imaging, and magnetization transfer imaging – quickly became a major tool for medical diagnosis and research on living creatures. Its applications to neurological disease are described in several other chapters of this book.
Magnetic resonance spectroscopy (MRS) is the designation used in the biomedical world for measurement of NMR signals from non-water protons and other magnetic nuclei. The usage is not accurate, MRI is the MRS of water, but it is convenient. MRS signals detectable in living brain are thousands of times weaker than the water proton signal; hence observing them requires extra time and special procedures. The reward for the effort is an abundance of chemically specific information which can be acquired as often as necessary, since the measurement process is non-invasive. In the living human brain, 1H signals can be obtained from N-acetyl aspartate, creatine, choline moieties, glutamate, glutamine, lactate, and several other small molecules. Phosphocreatine, adenosine triphosphate, and inorganic phosphate can be measured directly by their 31P signals, and intracellular pH calculated from its effect on these signals. Information from the 31P spectrum allows calculation of the rate of the creatine kinase reaction. The spectra of 13C, 15N, 17O, and other magnetic nuclei contain many more small signals from a variety of molecules which will become detectable as technology advances.
This unprecedented measurement capability provides an opportunity for characterization of human neurological diseases along several axes of chemical variation throughout their natural histories. The data are obtained without hazard to the patient, are free from artefacts of tissue preparation, and can be compared in as much detail as necessary to identically acquired information from normal subjects. As MRS matures technically over the first decades of the twenty-first century, it can be expected to take a place among the principal technologies contributing to illumination of disease processes and evaluation of new treatments.
- Type
- Chapter
- Information
- Diseases of the Nervous SystemClinical Neuroscience and Therapeutic Principles, pp. 146 - 159Publisher: Cambridge University PressPrint publication year: 2002